摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-amino-5-(3-chlorophenyl)-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrano[2,3-d]pyrimidine-6-carbonitrile

中文名称
——
中文别名
——
英文名称
7-amino-5-(3-chlorophenyl)-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrano[2,3-d]pyrimidine-6-carbonitrile
英文别名
7-amino-5-(3-chlorophenyl)-2,3,4,5-tetrahydro-2,4-dioxo-1H-pyrano[2,3-d]pyrimidine-6-carbonitrile;7-amino-5-(3-chlorophenyl)-6-cyano-5H-pyrano[2,3-d]pyrimidin-(1H,3H)-2,4-dione;7-amino-5-(3-chlorophenyl)-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile;7-amino-6-cyano-5-(3-chlorophenyl)-4-oxo-5H-pyrano[2,3-d]pyrimidinone;7-amino-5-(3-chlorophenyl)-4-hydroxy-2-oxo-3,5-dihydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile;7-amino-5-(3-chlorophenyl)-2,4-dioxo-1,5-dihydropyrano[2,3-d]pyrimidine-6-carbonitrile
7-amino-5-(3-chlorophenyl)-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrano[2,3-d]pyrimidine-6-carbonitrile化学式
CAS
——
化学式
C14H9ClN4O3
mdl
——
分子量
316.703
InChiKey
WPIAIRQLZSUJTL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    22
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.07
  • 拓扑面积:
    117
  • 氢给体数:
    3
  • 氢受体数:
    5

反应信息

  • 作为产物:
    描述:
    巴比妥酸3-氯苯甲醛丙二腈 在 NaHSO4 immobilized on core/shell phenylene bridged periodic mesoporous organosilica Fe3O4 nanoparticles 作用下, 以 为溶剂, 反应 0.23h, 以93%的产率得到7-amino-5-(3-chlorophenyl)-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrano[2,3-d]pyrimidine-6-carbonitrile
    参考文献:
    名称:
    Synthesis of Tetrahydrobenzo[b]pyran and Pyrano[2, 3-d]pyrimidinone Derivatives Using Fe3O4@Ph-PMO-NaHSO4 as a New Magnetically Separable Nanocatalyst
    摘要:
    在核/壳苯基桥联周期性介孔有机硅磁性纳米颗粒(Fe3O4@Ph-PMO-NaHSO4)上固定化的NaHSO4作为一种新型酸性磁性可分离纳米催化剂成功地通过三个步骤制备而成:(i)通过沉淀法制备Fe3O4纳米颗粒,(ii)合成具有苯基团的有机-无机周期性介孔有机硅结构,将其覆盖在Fe3O4磁性纳米颗粒(MNPs)表面,(iii)最后将NaHSO4吸附在周期性介孔有机硅(PMO)网络上。制备的有机-无机磁性试剂通过傅里叶变换红外光谱(FT-IR)、X射线粉末衍射(XRD)、透射电子显微镜(TEM)、N2吸附-脱附和能谱X射线(EDX)技术进行表征。最后,它被用作可重复使用的新型催化剂,促进四氢苯并[b]吡喃和吡喃并[2,3-d]嘧啶酮衍生物的合成,这些是重要的生物活性化合物。环保的方案、高产率、短反应时间以及产品的易于快速分离是该程序的主要优点。
    DOI:
    10.1166/jnn.2019.16032
点击查看最新优质反应信息

文献信息

  • Verjuice as a green and bio-degradable solvent/catalyst for facile and eco-friendly synthesis of 5-arylmethylenepyrimidine-2,4,6-trione, pyrano[2,3-d]pyrimidinone and pyrimido[4,5-d]pyrimidinone derivatives
    作者:Niloufar Safari、Farhad Shirini、Hassan Tajik
    DOI:10.1007/s13738-018-1565-y
    日期:2019.4
    of the synthesis of 5-arylmethylenepyrimidine-2,4,6-triones, via Knovenagel condensation reaction between barbituric or thiobarbituric acid and aldehydes. Verjuice is also employed for the effective synthesis of pyrano[2,3-d]pyrimidinone derivatives via a three-component reaction of barbituric acid or its thio analogue, aldehydes and malononitrile. In the same way, pyrimido[4,5-d]pyrimidinone derivatives
    Verjuice(未成熟的葡萄汁)是一种有机酸的天然混合物,可通过pH值和TGA分析鉴定,可通过Knovenagel缩合有效地用于促进5-芳基亚甲基嘧啶-2,4,6-三酮的合成。巴比妥酸巴比妥酸与醛之间的反应。Verjuice还用于通过巴比妥酸或其代类似物,醛和丙二腈的三组分反应有效合成喃并[2,3- d ]嘧啶酮衍生物。同样,嘧啶基[4,5- d]嘧啶酮衍生物可简单地通过巴比妥酸,醛与硫脲在果汁中的反应来制备。这种绿色方法学具有显着的优势,包括操作简单,可接受的反应时间,易于后处理,高收率,避免在反应和后处理过程中使用任何昂贵的起始原料,挥发性和有害有机溶剂以及使用天然,低成本,可重复使用且可生物降解的催化剂。
  • Introduction of organic/inorganic Fe<sub>3</sub>O<sub>4</sub>@MCM-41@Zr-piperazine magnetite nanocatalyst for the promotion of the synthesis of tetrahydro-4<i>H</i>-chromene and pyrano[2,3-<i>d</i>]pyrimidinone derivatives
    作者:Reyhaneh Pourhasan-Kisomi、Farhad Shirini、Mostafa Golshekan
    DOI:10.1002/aoc.4371
    日期:2018.7
    highly dispersed in the tetrahedral environment of silica framework and piperazine is successfully attached to the surface of the nanocatalyst in connection with zirconium. The prepared nanosized reagent (10–30 nm), shows excellent catalytic activity in the synthesis of tetrahydro‐4H‐chromene and pyrano[2,3‐d]pyrimidinone derivatives. All reactions are performed under mild and completely heterogeneous
    哌嗪修饰的Fe 3 O 4 @ MCM-41 @ Zr-MNPs易于制备,并使用傅里叶变换红外光谱(FT-IR),X射线粉末衍射(XRD),N 2吸附-解吸,透射电子显微镜进行表征( TEM),能量色散X射线(EDX),振动样品磁力法(VSM)和热重分析(TGA)技术。表征结果表明,高度分散在二氧化硅骨架和哌嗪的四面体环境中的Zr可以成功地附着在与相关的纳米催化剂表面。制备的纳米级试剂(10–30 nm)在四氢-4 H-色烯和喃[2,3- d]嘧啶酮衍生物。所有反应均在温和且完全异质的反应条件下进行,且反应时间短。另一方面,由于其超顺磁性,该催化剂可通过施加外部磁场容易地分离并重复使用多次。
  • Succinimidinium N-sulfonic acid hydrogen sulfate as an efficient ionic liquid catalyst for the synthesis of 5-arylmethylene-pyrimidine-2,4,6-trione and pyrano[2,3-d]pyrimidinone derivatives
    作者:Masoumeh Abedini、Farhad Shirini、Javad Mohammad-Alinejad Omran、Mohadeseh Seddighi、Omid Goli-Jolodar
    DOI:10.1007/s11164-015-2289-6
    日期:2016.5
    ([SuSA-H]HSO4) as a new ionic liquid is prepared and characterized using a variety of techniques, including infrared spectra (FT-IR), 1H and 13C NMR, scanning electron microscopy, a mass spectra method, as well as by Hammett acidity function. The prepared reagent is efficiently able to catalyze the preparation of 5-arylmethylene-pyrimidine-2,4,6-triones via the condensation of aldehydes and barbituric acid
    使用多种技术制备并表征了琥珀酰亚胺 N- 磺酸硫酸氢盐([SuSA-H] HSO 4),并使用多种技术进行了表征,包括红外光谱(FT-IR),1 H和13 C NMR,扫描电子显微镜,质谱方法以及Hammett酸度函数。通过醛和巴比妥酸的缩合,所制备的试剂能够有效地催化5-芳基亚甲基-嘧啶-2,4,6-三酮的制备。进一步的研究表明,醛与巴比妥酸丙二腈的缩合反应生成喃并[2,3- d 在该试剂的存在下,也可以有效地促进]嘧啶酮衍生物。本发明的方法具有几个优点,包括易于制备和处理催化剂,简单和容易的后处理,短的反应时间,产物的高产率和催化剂的可回收性。
  • Comparison of the efficiency of two imidazole-based dicationic ionic liquids as the catalysts in the synthesis of pyran derivatives and Knoevenagel condensations
    作者:Zahra Sharifi、Nader Daneshvar、Mohaddeseh Safarpoor Nikoo Langarudi、Farhad Shirini
    DOI:10.1007/s11164-019-03874-5
    日期:2019.10
    ([C4(MIm)2]·2HSO4) were prepared via adequate, solvent-free methods and characterized using FT-IR, 1H NMR, 13C NMR, and potentiometric titration techniques. These reagents were investigated in the synthesis of 5-arylidene (thio)barbituric acids, 2-arylidene malononitriles, 4H-pyrans, and pyrano[2,3-d] pyrimidineones, and their catalytic activities were compared in the promotion of these reactions. Based
    在目前的工作中,使用3,3'-(1-丁烷1,4-丁二)双(1-甲基-1 H-咪唑-3-鎓)二化物([C 4(MIm)2 ]·2Cl)和3,通过适当的,无溶剂的方法制备了3 ' -(丁烷-1,4-二基)双(1-甲基-1 H-咪唑-3-鎓)硫酸氢盐[[C 4(MIm)2 ]·2HSO 4) FT-IR,1 H NMR,13 C NMR和电位滴定技术进行表征。在合成5-芳基(代)巴比妥酸,2-芳基丙二腈,4 H-喃和喃并[2,3- d]时对这些试剂进行了研究。比较嘧啶酮及其催化活性,以促进这些反应。根据获得的结果,我们发现[C 4(MIm)2 ]·2Cl在需要碱性或弱酸性介质的情况下显示出更高的催化效率。相反,在需要酸性催化剂以提高反应速率的反应中,[C 4(MIm)2 ]·2HSO 4是强大的催化剂。使用这些试剂,可以在较短的反应时间内,在温和,环保的条件下以优异的收率形成产物,而无需使用柱色谱进行后处理。
  • Glycerol as a biodegradable and reusable promoting medium for the catalyst-free one-pot three component synthesis of 4H-pyrans
    作者:Hamid Reza Safaei、Mohsen Shekouhy、Sudabeh Rahmanpur、Athar Shirinfeshan
    DOI:10.1039/c2gc35135h
    日期:——
    Glycerol is applied as a green, biodegradable and reusable promoting medium for one-pot three component synthesis of 4H-pyrans under catalyst-free conditions. A broad range of substrates including aromatic and heteroaromatic aldehydes, isatine derivatives, acenaphthenequinone and ninehydrine are condensed with carbonyl compounds possessing a reactive α-methylene group and alkylmalonates. All reactions are completed in short times, and the products are obtained in good to excellent yields. The reaction medium could be recycled and reused several times without any loss of efficiency.
    甘油作为绿色、生物可降解且可重复利用的促进介质,在无催化剂条件下用于一锅法三组分合成4H-吡喃。广泛的一系列底物,包括芳香和杂环醛、吲哚醌衍生物苊醌和九氢吲哚,与具有活性α-亚甲基的羰基化合物及烷基丙二酸酯进行缩合反应。所有反应均在短时间内完成,产物收率良好至优异。反应介质可回收并重复使用多次,效率无任何损失。
查看更多

同类化合物

叔-丁基2-(甲磺酰)-5,7-二氢螺[吡喃并[4,3-D]嘧啶并-8,3-吡咯烷]-1-甲酸基酯 乙基7'-氨基-6-氟-2,2',4'-三羰基-1,1',2,2',3',4'-六氢螺[吲哚-3,5'-吡喃并[2,3-d]嘧啶]-6'-羧酸酯 7H-吡喃并[2,3-d]嘧啶-7-酮 7H-吡喃并[2,3-d]嘧啶 7,8-二氢-5H-吡喃并[4,3-D]嘧啶-2-胺 5H-吡喃并[4,3-d]嘧啶 5H-吡喃并[2,3-d]嘧啶 2H-吡喃并[2,3-d]嘧啶-6-甲腈,7-氨基-1,3,4,5-四氢-5-(4-甲氧苯基)-2,4-二羰基- 2,4-二氯-7,8-二氢-5H-吡喃[4,3-d]嘧啶 1H-吡喃并[3,4-d]嘧啶 1H-吡喃并[3,2-d]嘧啶 (5S,7R,8S)-2-methylsulfanyl-5,8-dihydro-7-allyloxymethyl-5-methoxy-pyrano[3,4-d]-pyrimidin-8-ol 5-ethyl-2-[(Z)-1-thiophen-3-ylpentylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 5-ethyl-2-[[1-(3-methylbutanoyl)piperidin-4-ylidene]amino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 5-butyl-2-[(E)-1-(4-cyclohexylpiperazin-1-yl)butylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 2,3,3a,9-tetrahydro-5-iodo-2,3,3-trimethylimidazo[5,1-b][1,3]benzoxazin-1-one 2,4-dimethyl-9-methoxy-4,12b-dihydro-1H,7H-chromeno[4',3'-4,5]pyrano[2,3-d]pyrimidine-1,3(2H)-dione 5-methyl-3-{3-[(R)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-propyl}-1H-quinazoline-2,4-dione 7-amino-2-(benzothiazol-2-ylmethyl)-9-phenylthiazolo[4',5':6,5]pyrano[2,3-d]pyrimidine-8(7H)-one 2-[6-[(2-chlorophenyl)methyl]pyridin-2-yl]-7,8-dihydro-5H-pyrano[4,3-d]pyrimidine 8-amino-2-(methylthio)-5-oxo-6-(pyridin-4-yl)-5,6-dihydro-4H-pyrano[2,3-d][1,3]thiazolo[4,5-b]pyridine-7-carbonitrile 5-(4-chlorophenyl)-1,3,8,8-tetramethyl-7,9-dihydro-5H-chromeno[2,3-d]pyrimidine-2,4,6-trione ethyl 7'-amino-2,4'-dioxo-2'-thioxo-1,1',2,2',3',4'-hexahydrospiroindole-3,5'-pyrano[2,3-d]pyrimidine-6'-carboxylate 8-amino-2-(methylthio)-5-oxo-6-(pyridin-3-yl)-5,6-dihydro-4H-pyrano[2,3-d][1,3]thiazolo[4,5-b]pyridine-7-carbonitrile 7-Amino-4-oxo-5-phenyl-2-thioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carboxylic acid ethyl ester 3-(1H-benzoimidazol-2-yl)-3-butyl-5-methyl-dihydro-furan-2-one 3-(1H-benzoimidazol-2-yl)-3-(2-diethylamino-ethyl)-5-methyl-dihydro-furan-2-one 1-{4-[(1R,9S)-3-((S)-3-methyl-morpholin-4-yl)-12-oxa-4,6-diaza-tricyclo[7.2.1.0-2,7]dodeca-2(7),3,5-trien-5-yl]-phenyl}-3-oxetan-3-yl-urea (S)-6-(4-(4-(3-ethylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenylamino)pyridin-2(1H)-one 3-(1H-benzoimidazol-2-yl)-5-methyl-3-(3-methyl-butyl)-dihydro-furan-2-one 13-(3,4-dimethoxyphenyl)-5,5-dimethyl-2-thioxo-2,5,6,8,9,13-hexahydro-4H-pyrimido[5',4':6,7][1,8]naphthyridino[4,3,2-de]quinazoline-10,12(3a1H,11H)-dione (S)-3-allyl-8-ethyl-4,7-dioxo-2-(phenylcarbamoyl)-4,5,7,8-tetrahydro-3H-pyrano[4,3-d]pyrimidin-8-yl acetate 8-{[(2-bromo-3-methylphenyl)oxy]methyl}-1,3-dimethyl-2,3,4,6-tetrahydro-1H-pyrano[3,2-d]pyrimidine-2,4-dione 9-ethyl-6a-methyl-2-phenyl-8,9-dihydro-oxazolo[2,3-b]pyrimido[4,5-d][1,3]oxazin-5-one (S)-1-cyclobutyl-3-(4-(4-(3-methylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenyl)urea (S)-2-(4-(4-(3-ethylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenylamino)pyrimidin-4(3H)-one (6aRS,10aRS)-4,6,6a,7,8,9,10,10a-octahydro-2,4,6,6-tetramethyl-1H-<2>benzopyrano<3,4-d>pyrimidine-1,3(2H)-dione 5-ethyl-2-[(E)-1-thiophen-3-ylpentylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione N3-(methyl 4-deoxy-α-L-threo-hex-4-enopyranosyluronate)-5-fluorouracil 1-{4-[(1S,9R)-3-((S)-3-methyl-morpholin-4-yl)-12-oxa-4,6-diaza-tricyclo[7.2.1.0-2,7]dodeca-2(7),3,5-trien-5-yl]-phenyl}-3-oxetan-3-yl-urea 4,5-dimethyl-12-(4-methoxyphenyl)-2-thioxo-2,4a,7,8,9,10,11,12-octahydrodipyrimido[4,5-b;4',5'-f] [1,8]naphthyridine-9,11-dione 2-[4-[2-hydroxyethyl(methyl)amino]-2-methyl-7-oxopyrimido[5,4-b][1,4]oxazin-8-yl]acetonitrile 5-ethyl-2-[(Z)-1-thiophen-2-ylethylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione